CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project seeks to develop innovative protein-based therapeutics targeting intracellular oncoproteins involved in cancer. By engineering monobodies and delivery systems, the research aims to overcome limitations of current cancer treatments and improve therapeutic options.
Oncogenic signalling networks display a remarkable degree of plasticity.
Despite only a limited number of alterations in oncogenes and tumour suppressor genes in most tumours, the majority of targeted therapeutics (monoclonal antibodies and small-molecule kinase inhibitors) does not strongly improve the survival of cancer patients and suffers from the rapid development of resistance.
The rising number of targeted drugs in clinical use inhibits only a very limited number of protein targets (large…
PHILIPPS UNIVERSITAET MARBURG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Switzerland, Lausanne
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
